Allison Hagerman Purchases 10,000 Shares of Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC) insider Allison Hagerman purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average price of C$1.14 per share, for a total transaction of C$11,400.00. Following the completion of the transaction, the insider directly owned 79,842 shares in the company, valued at C$91,019.88. This trade represents a 14.32% increase in their ownership of the stock.

Oncolytics Biotech Stock Performance

Oncolytics Biotech Inc. has a 1-year low of C$0.44 and a 1-year high of C$2.08. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The firm’s 50-day moving average price is C$14.90 and its 200 day moving average price is C$13.11. The firm has a market capitalization of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech (TSE:ONC) last issued its earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share for the quarter. Analysts predict that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.